| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |